1. |
Fang M, Toher J, Morgan M, et al.Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis[J].Cancer, 2011, 117(10):2024-2034.
|
2. |
Gruver AM, Portier BP, Tubbs RR.Molecular pathology of breast cancer:the journey from traditional practice toward embracing the complexity of a molecular classification[J].Arch Pathol Lab Med, 2011, 135(5):544-557.
|
3. |
Coleman RE, Rubens RD.The clinical course of bone metastases from breast cancer[J].Br J Cancer, 1987, 55(1):61-66.
|
4. |
Jemal A, Bray F, Center MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61(2):69-90.
|
5. |
Mundy GR.Metastasis to bone:causes, consequences and therapeutic opportunities[J].Nat Rev Cancer, 2002, 2(8):584-593.
|
6. |
Scheid V, Buzdar AU, Smith TL, et al.Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy[J].Cancer, 1986, 58(12):2589-2593.
|
7. |
Fox EM, Andrade J, Shupnik MA.Novel actions of estrogen to promote proliferation:Integration of cytoplasmic and nuclear pathways[J].Steroids, 2009, 74(7):622-627.
|
8. |
孙燕, 石远凯.临床肿瘤内科手册[M].第5版.北京:人民卫生出版社, 2007:920-921.
|
9. |
Goldhirsch A, Wood WC, Coates AS, et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast cancer 2011[J].Ann Oncol, 2011, 22(8):1736-1747.
|
10. |
Rogers MJ, Gordon S, Benford HL, et al.Cellular and molecular mechanisms of action of bisphosphonates[J].Cancer, 2000, 88(12 Suppl):2961-2978.
|
11. |
Selander K, Lehenkari P, Väänänen HK.The effects of bisphosphonates on the resorption cycle of isolated osteoclasts[J].Calcif Tissue Int, 1994, 55(5):368-375.
|
12. |
Murakami H, Takahashi N, Sasaki T, et al.A possible mechanism of the specific action of bisphosphonates on osteoclasts:tiludronate preferentially affects polarized osteoclasts having ruffled borders[J].Bone, 1995, 17(2):137-144.
|
13. |
Pike MC, Spicer DV, Dahmoush L, et al.Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk[J].Epidemiol Rev, 1993, 15(1):17-35.
|
14. |
Clemons M, Goss P.Estrogen and the risk of breast cancer[J].N Engl J Med, 2001, 344(4):276-285.
|
15. |
Clarke R, Leonessa F, Welch JN, et al.Cellular and molecular pharmacology of antiestrogen action and resistance[J].Pharmacol Rev, 2001, 53(1):25-71.
|
16. |
Clarke RB, Howell A, Potten CS, et al.Dissociation between steroid receptor expression and cell proliferation in the human breast[J].Cancer, 1997, 57(22):4987-4991.
|
17. |
Russo J, Ao X, Grill C, et al.Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland[J].Breast Cancer, 1999, 53(3):217-227.
|
18. |
Seagroves TN, Lydon JP, Hovey RC, et al.C/EBPbeta (CCAAT/enhancer binding protein) controls cell fate determination during mammary gland development[J].Mol Endocrinol, 2000, 14(3):359-368.
|
19. |
林颖.双膦酸盐临床试验最新进展--2011年SABCS会议速递[J].药品评价, 2012, 9(6):24-25.
|
20. |
邵志敏, 沈镇宙, 徐兵河, 等.乳腺肿瘤学[M].上海:复旦大学出版社, 2013:474-478.
|
21. |
Coleman R, Marshall H, Gregory W, et al.5019 poster discussion discordant treatment effects according to menopausal status following adjuvant zoledronic acid in stageⅡ/Ⅲbreast cancer.The AZURE trial (BIG 01/04)[J].Eur J Cancer, 2011, 47(1):s336.
|
22. |
邵淑丽, 李秀云, 杨金存, 等.女性性腺激素水平与乳腺疾病的相关性研究[J].医学检验与临床, 2009, 20(1):21-23.
|
23. |
Schenk R, Eggli P, Fleisch H, et al.Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat[J].Calcif Tissue Int, 1986, 38(6):342-349.
|
24. |
Russell RG, Xia Z, Dunford JE, et al.Bisphosphonates:an update on mechanisms of action and how these relate to clinical efficacy[J].Ann N Y Acad Sci, 2007, 1117:209-257.
|